Transdermal therapeutic system
First Claim
1. Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient, and/or an active ingredient reservoir;
- a diffusion barrier which is permeable to active ingredients and which is arranged on the skin side of the active ingredient reservoir; and
an ergoline derivative according to Formula I or physiologically compatible salt thereof with an acid,
3 Assignments
0 Petitions
Accused Products
Abstract
Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy. The invention relates to the use of a transdermal therapeutic system (TTS) comprising a medicinal layer, which contains at least one matrix comprising an active ingredient and/or an active ingredient reservoir and a diffusion barrier situated on the skin side of the active ingredient reservoir and permeable to active ingredients, in addition to, an ergoline-derivative or physiologically compatible salt with an acid thereof, as an active ingredient, for producing a means for treating the restless-legs-syndrome. The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparations for oral and/or parenteral application containing that same dopaminergic agent for the treatment of dopaminergically treatable diseases with the following elements: a) the TTS is continuously applied, b) within the duration of application in a) the composition for oral or parenteral dosage is administered. The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat-soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.-butylmetoxyphenols, tocopherols or ubichinones and a basic polymer.
-
Citations
52 Claims
-
1. Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient, and/or an active ingredient reservoir;
- a diffusion barrier which is permeable to active ingredients and which is arranged on the skin side of the active ingredient reservoir; and
an ergoline derivative according to Formula I or physiologically compatible salt thereof with an acid, - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
- a diffusion barrier which is permeable to active ingredients and which is arranged on the skin side of the active ingredient reservoir; and
- 12. A TTS set for the treatment of circadian disturbances under dopamine therapy wherein the set contains a multitude of TTS elements and wherein said elements are configured for releasing different doses.
-
15. Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient, and/or an active ingredient reservoir;
- a diffusion barrier which is permeable to active ingredients and which is arranged on the skin side of the active ingredient reservoir; and
an ergoline derivative according to Formula I or physiologically compatible salt thereof with an acid, - View Dependent Claims (16, 17, 18, 19, 20, 21, 22, 23)
- a diffusion barrier which is permeable to active ingredients and which is arranged on the skin side of the active ingredient reservoir; and
-
24. Use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparations for oral and/or parenteral application containing that same dopaminergic agent for the treatment of dopaminergically treatable diseases with the following elements, where
a) the TTS is applied continuously, b) within the duration of application in a) the preparation for oral or parenteral dosage is administered.
-
38. A combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing one and the same dopamine agonist with a short half-life to produce a pharmaceutical for the treatment of dopaminergic diseases.
- 39. A medication for transdermal application consisting of an impermeable backing layer, an ergoline compound and possibly a penetration enhancers containing matrix, possibly a diffusion barrier covering the matrix, a layer of adhesive permeable for these substances and a peel-off protective cover, characterized by a stabilization of the ergoline compounds through an antioxidant and a basic polymer.
Specification